Xigris (drotrecogin alfa)  should be administered intravenously at an infusion rate of 24 mcg/kg/hr   (based on actual body weight) for a total duration of infusion of 96 hours.   Dose adjustment based on clinical or laboratory measurements is not recommended   [see DRUG INTERACTIONS]. Dose escalation or bolus doses of Xigris (drotrecogin alfa)  are   not recommended.
If the infusion is interrupted, Xigris (drotrecogin alfa)  should be restarted at the 24 mcg/kg/hr infusion rate.
In the event of clinically important bleeding, immediately stop the infusion    [see WARNINGS AND PRECAUTIONS].
Xigris (drotrecogin alfa)  should be administered via a dedicated intravenous line or a dedicated lumen of a multilumen venous catheter. The ONLY other solutions that can be administered through the same line are 0.9% Sodium Chloride Injection, USP; Lactated Ringer's Injection, USP; Dextrose Injection, USP; and Dextrose and Sodium Chloride Injection, USP.
Avoid exposing Xigris (drotrecogin alfa)  solutions to heat and/or direct sunlight. Studies conducted at the recommended concentrations indicate the Xigris (drotrecogin alfa)  intravenous solution to be compatible with glass infusion bottles, and infusion bags and syringes made of polyvinylchloride, polyethylene, polypropylene, or polyolefin.
Note: Reconstitute vials of lyophilized Xigris (drotrecogin alfa)  only with Sterile Water for   Injection, USP.
Complete “Preparation of Concentrated Solution” steps 1-6 above, then complete    the next 7 steps.
Complete “Preparation of Concentrated Solution” steps 1-6 above, then complete    the next 7 steps.
